Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma
| Autor: | Angelo Agretto, A. Iacono, M. Giuliano, Diana Iarussi, A. Murano, Paolo Indolfi, Fiorina Casale, U. Auricchio |
|---|---|
| Přispěvatelé: | Iarussi, D, Auricchio, U, Agretto, A, Murano, A, Giuliano, M, Casale, Fiorina, Indolfi, P, Iacono, A. |
| Rok vydání: | 1994 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty Adolescent Ubiquinone Lymphoblastic Leukemia Clinical Biochemistry Coenzymes Biochemistry Gastroenterology Ventricular Function Left chemistry.chemical_compound Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Interventricular septum Child Molecular Biology Coenzyme Q10 Cardiotoxicity Cumulative dose business.industry Lymphoma Non-Hodgkin Daunorubicin food and beverages General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Lymphoma medicine.anatomical_structure Treatment Outcome chemistry Echocardiography Immunology Molecular Medicine Hodgkin lymphoma business Cardiomyopathies |
| Zdroj: | Molecular aspects of medicine. |
| ISSN: | 0098-2997 |
| Popis: | Two groups of children with acute lymphoblastic leukemia or non-Hodgkin lymphoma, treated with anthracyclines (ANT), were studied: group I, consisting of 10 patients, with coenzyme Q10 (CoQ) therapy; group II, consisting of 10 patients without CoQ therapy. The ANT cumulative dose was 240 +/- 20.0 mg/m2 in group I and 252.0 +/- 20.1 mg/m2 in group II. Echocardiographic study was performed at the beginning, at the cumulative dose of 180 mg/m2 and at the end of therapy with ANT. Percentage left ventricular fractional shortening (%LVFS) decreased from baseline (40.36 +/- 4.6) to end value (35.82 +/- 5.02) (P < 0.05) in group I; %LVFS decreased from baseline (39.89 +/- 4.37) to end value (33.43 +/- 3.46) (P < 0.002) in group II. Interventricular septum wall thickening decreased only in group II from baseline (46.10 +/- 10.1) to end therapy (27.00 +/- 18.54) (P < 0.01). Septum wall motion abnormalities were detected only in 2 patients of group II. These data demonstrate a protective effect of CoQ on cardiac function during therapy with ANT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|